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Research
In 2004, South Korean investigators reported 
nine cases of a disease thought to have been 
eliminated decades before: acute beryllium dis­
ease (ABD) (Kim et al. 2004). The recognition 
of new cases, the projected growth in world­
wide demand for beryllium for applications 
including nuclear energy production (U.S. 
Department of Energy 2008) and national 
defense (Business Wire 2005), and advances in 
the understanding of chronic beryllium disease 
(CBD) led us to reconsider the pathogenesis 
of ABD. The resulting reconceptualization has 
implications for prevention, diagnosis, and case 
management in the global beryllium industry.
Textbooks and review articles have stated 
that exposure to beryllium may result in two 
distinct respiratory conditions. ABD is consid­
ered to be an irritative chemical phenomenon, 
whereas CBD is recognized as an immune­
mediated granulomatous process (Balmes 2005; 
Becklake and Cowie 2000; Churg and Green 
1998; Williams 1988). This conceptualization 
began > 50 years ago, with the assertions that 
ABD followed a traditional exposure–response 
pattern and was associated with airborne beryl­
lium concentrations > 100 µg/m3, whereas 
CBD could occur at much lower levels, indi­
cating an immune phenome  non (Sterner and 
Eisenbud 1951). Although the description 
of ABD has remained essentially static, the 
understanding of CBD has evolved greatly 
in recent decades. It is now well established 
that sensitization to beryllium, as measured 
by the beryllium lymphocyte proliferation test 
(BeLPT), reflects cellular immune recogni­
tion of beryllium and confers a higher risk of 
subsequent development of CBD (Kreiss et al. 
2007; Mroz et al. 1991; Newman et al. 2005; 
Sawyer et al. 2002). CBD can be detected at 
a sub  clinical stage by bronchoalveolar lavage 
(BAL) and biopsy (Cordeiro et al. 2007; Maier 
2001). Lymphocyte predominance and abnor­
mal BeLPT on BAL fluid analysis are findings 
consistent with CBD.
Acute respiratory and dermal reactions to 
beryllium exposure were first reported in the 
United States in the 1940s, observed among 
workers in the beryllium extraction and pro­
cessing industry (DeNardi et al. 1949; Van 
Ordstrand et al. 1945). A relation  ship with 
exposure to soluble beryllium salts (sulfate 
and fluoride) and soluble forms of the oxide 
was noted by early investigators (Eisenbud 
1982; Eisenbud et al. 1948). During that era, 
daily weighted average (DWA) exposures to 
beryllium were known to exceed 1,000 µg/m3 
in certain operations (Eisenbud 1982).
In 1949, the U.S. Atomic Energy 
Commission recommended two different 
occupational exposure limits to their con­
tractors: 25 µg/m3 as a maximum permis­
sible peak exposure, to prevent ABD, and 
2 µg/m3 as a DWA over a quarterly period, 
to prevent CBD (Eisenbud 1982). These 
limits were subsequently adopted in the 
United States by various professional organiza­
tions and the Occupational Safety and Health 
Administration, and regulatory bodies in many 
other countries also recognize the 2 µg/m3 limit 
(Eisenbud 1982, 1998). Over time, average 
exposures have decreased from hundreds of 
micrograms per cubic meter in the 1940s and 
1950s to ≤ 1 µg/m3 in the 1980s and 1990s 
(National Research Council 2008).
Beryllium fluoride is intentionally formed 
during the production of beryllium metal. In 
the initial step, ammonium beryllium fluo­
ride is heated in a fluoride furnace to drive off 
ammonium fluoride gas and yield beryllium 
fluoride (Kroschwitz and Howe­Grant 1992; 
White and Burke 1955). The beryllium fluo­
ride then is transferred to an adjacent reduc­
tion furnace and reacted with magnesium 
to yield beryllium metal. In this article, we 
describe two cases of acute respiratory and der­
mal illness that occurred in workers involved 
in beryllium metal production. The extensive 
diagnostic evaluations that they underwent 
provide details on pathogenesis that were not 
available in earlier reports of ABD. In light of 
these cases and a review of the historical lit­
erature, we suggest that rather than being two 
distinct clinical entities, ABD and CBD repre­
sent points on a continuum of hypersensitivity 
reactions to beryllium.
methods
Cases were identified through a survey of 
workers at a beryllium manufacturing plant 
producing pure metal, oxide, and alloys 
(Kreiss et al. 1997). To prepare the case 
reports, we reviewed medical records of care 
provided in the plant’s medical clinic or at 
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tous reaction to beryllium, acute beryllium disease (ABD) is commonly considered an irritative 
chemical phenomenon related to high exposures. Given reported new cases of ABD and projected 
increased demand for beryllium, we aimed to reevaluate the patho  physiologic associations between 
ABD and CBD using two cases identified from a survey of beryllium production facility workers.
ca s e Pr e s e n t a t i o n: Within weeks after exposure to beryllium fluoride began, two workers had 
systemic illness characterized by dermal and respiratory symptoms and precipitous declines in pul-
monary function. Symptoms and pulmonary function abnormalities improved with cessation of 
exposure and, in one worker, recurred with repeat exposure. Bronchoalveolar lavage fluid analyses 
and blood beryllium lymphocyte proliferation tests revealed lymphocytic alveolitis and cellular 
immune recognition of beryllium. None of the measured air samples exceeded 100 µg/m3, and most 
were < 10 µg/m3, lower than usually described. In both cases, lung biopsy about 18 months after 
acute illness revealed non  caseating granulomas. Years after first exposure, the workers left employ-
ment because of CBD.
discussion: Contrary to common understanding, these cases suggest that ABD and CBD represent 
a continuum of disease, and both involve hypersensitivity reactions to beryllium. Differences in dis-
ease presentation and progression are likely influenced by the solubility of the beryllium compound 
involved.
relevance t o Pr a c t i c e: ABD may occur after exposures lower than the high concentrations com-
monly described. Prudence dictates limitation of further beryllium exposure in both ABD and CBD.
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referral health care facilities and examined 
chest radio  graphs taken in the plant’s medi­
cal clinic. We used the plant’s air sampling 
data to characterize exposures that occurred 
before symptom onset. Air measurements 
included short­duration (< 30 min) breathing 
zone (BZ) air samples, short­ or long­duration 
(5 min to 8 hr) general area (GA) air samples, 
and DWA exposures calculated by combining 
the GA and BZ air samples with information 
on typical amount of time spent at different 
locations and activities by job titles. From 
these GA or BZ sample data, we selected the 
highest time­weighted average (TWA) beryl­
lium concentration on any given day from 
the work areas or activities associated with 
a worker’s job and tenure. Each case is pre­
sented with the worker’s written permission 
and institutional review board approval.
Case 1
A healthy 20­year­old male non  smoker began 
working at the beryllium production plant on 
12 March 1979. His pre  employment chest 
radiograph was normal (Figure 1A) and pul­
monary function tests were normal, includ­
ing a forced vital capacity (FVC) of 6.34 L 
(120% predicted) and a carbon monoxide 
diffusing capacity (DLCO) of 39.5 mL/min/
mmHg (119% predicted) (Figure 2A). After 
time in the ceramics and alloy fabrication 
departments (Kent et al. 2001; Stefaniak et al. 
2003, 2004), during which routine pulmo­
nary function tests were normal, he was trans­
ferred on 31 December 1979 to the metal 
production department to operate the reduc­
tion furnace (Kent et al. 2001; Kroschwitz 
and Howe­Grant 1992; Stefaniak et al. 
2003, 2004; White and Burke 1955). On 
12 January 1980, he presented to the plant’s 
medical office complaining of a new rash on 
both forearms and was seen multiple times for 
the rash over the next month.
On 29 March 1980, the patient com­
plained of shortness of breath, chest pain, and 
a non  productive cough that had begun several 
weeks earlier. He had lost 2.7 kg over the 
preceding month. Pulmonary function test­
ing demonstrated a substantial fall in FVC, 
to 3.41 L (64% predicted), and a decrease 
in DLCO, to 8.9 mL/min/mmHg (27% pre­
dicted). The chest radiograph was normal. 
On 1 April 1980, a company physician noted 
“scattered rales” on chest examination and 
restricted the patient from further work.
While on work restriction, the patient 
was treated with antibiotics and antitussives. 
His FVC reached a nadir of 2.84 L (54% 
predicted) on 4 April 1980, increasing over 
the next month to 4.90 L (90% predicted); 
the DLCO improved to 31.2 mL/min/mmHg 
(94% predicted). By the end of April, his 
weight had returned to baseline and he no 
longer had a cough.
On 28 April 1980, the patient returned 
to work in the metal production department, 
intermittently as a reduction furnace operator. 
In July and August, he was seen multiple times 
for rash and skin ulcers on the wrist and hand. 
In early September, he described a produc­
tive cough and his FVC had fallen to 4.63 L 
(88% predicted). By 11 October 1980, he 
had lost 7.7 kg and reported progressive cough 
and exertional dyspnea. His FVC at that time 
was 4.33 L (83% predicted), with a DLCO of 
24.8 mL/min/mmHg (78% predicted). His 
chest radio  graph was normal. A BeLPT drawn 
on 21 October 1980 was normal (stimulation 
index of 1.4).
Over the next several months the patient 
continued to work despite persistent symp­
toms. Repeat pulmonary function testing on 
2 December 1980 showed further declines 
in FVC, to 3.61 L (68% predicted), and in 
DLCO, to 20.0 mL/min/mmHg (62% pre­
dicted). On 2 February 1981, his FVC had 
fallen further, to 2.83 L (52% predicted). A 
month later, the patient was put on medical 
leave and blood was again drawn for BeLPT. 
That test and a repeat drawn on 17 March 
1981 were abnormal (stimulation indices of 
9.2 and 11.4, respectively). A chest radio­
graph that same day was remarkable for a 
mild diffuse nodular infiltrate (Figure 1B,C). 
In early April, BAL at the National Institutes 
of Health (NIH) revealed 47% lymphocytes.
In the ceramics and alloy departments, the 
patient was likely exposed to insoluble beryl­
lium (e.g., beryllium oxide). In the metal pro­
duction department, he was likely exposed to 
soluble (e.g., beryllium fluoride) and insoluble 
forms of beryllium and other irritants (e.g., 
ammonium fluoride). The highest TWA GA 
or BZ samples collected on any given day 
from the work areas or activities associated 
with his jobs during his tenure are displayed in 
Figure 2B, showing that none of the measured 
air samples exceeded 100 µg/m3 and that most 
were < 10 µg/m3. In the reduction furnace, 
molten beryllium is poured into pots that are 
carried via a conveyor to a cooling bay. During 
a 45­min period on 2 March 1980, the patient 
entered the cooling bay twice to conduct repair 
work on the conveyor, wearing a negative­
pressure half­face respirator. The furnace had 
just finished pouring, such that the fumes in 
the cooling bay were considered by the com­
pany to be very heavy. The sampling on that 
shift showed an 8­hr TWA of 5.9 µg/m3.
During 3 months away from work (March–
June 1981), the patient’s symptoms resolved 
and his pulmonary function normalized 
Figure 1. Chest radiographs of case 1. (A) Radiograph taken pre  hire on 2 March 1979, showing normal lung 
fields. (B) Radiograph taken during the second episode of acute work-related illness on 17 March 1981, 
showing a mild diffuse nodular infiltrate; (C) close-up of the right lower lung field from radiograph in (B). 
(D) Radiograph at follow-up on 13 February 1997, showing reduced lung volumes and a bilateral interstitial 
infiltrate. Cummings et al.
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(Figure 2). He returned to work on 15 June 
1981, now in the alloy department; he was 
restricted from working in the furnace area. He 
remained asymptomatic, but with a persistently 
elevated lymphocyte count (37–49%) on BAL 
performed on six occasions from June 1981 to 
December 1982. A transbronchial biopsy per­
formed at the NIH on 3 January 1983 revealed 
peri  bronchial non  caseating granulomas. Fungal 
stains of the tissue were negative. A follow­up 
chest radiograph taken in 1997 (Figure 1D) 
demonstrated reduced lung volumes and a 
bilateral interstitial infiltrate. He left the plant 
in 1999 because of CBD.
Case 2
A healthy 25­year­old male smoker began 
working at the beryllium production plant 
on 11 May 1981. His pre  employment 
chest radio  graph and pulmonary func­
tion tests were normal, including an FVC 
of 5.33 L (115% predicted) and a DLCO 
of 31.6 mL/min/mmHg (114% predicted) 
(Figure 3). He worked in the metal produc­
tion department operating the fluoride furnace 
(Kent et al. 2001; Kroschwitz and Howe­Grant 
1992; Stefaniak et al. 2003, 2004; White and 
Burke 1955). On 22 May 1981, he presented 
to the plant’s medical office with a new rash on 
the wrists and forearms and was seen multiple 
times for rash and skin ulcers over the next 
month. On 16 June 1981, a company physi­
cian evaluating him for new onset of recurrent 
epistaxis noted eroded nasal mucosa bilaterally.
On 26 June 1981 the patient complained 
of fatigue, shortness of breath, and non­
productive cough that had begun 1–2 weeks 
earlier. Pulmonary function testing demon­
strated a fall in FVC, to 4.82 L (104% pre­
dicted), and a decrease in DLCO, to 27.1 mL/
min/mmHg (99% predicted). His chest 
radiograph was normal. On 1 July 1981, a 
company physician noted rhonchi (sounds 
commonly caused by secretions in airways) 
on chest examination, prescribed a deconges­
tant and an antihistamine, and restricted the 
patient from further work. 
In the metal production department, 
the patient was likely exposed to soluble and 
insoluble forms of beryllium and other irri­
tant exposures. Figure 3B displays the high­
est TWA GA or BZ samples collected on 
any given day from the work areas or activi­
ties associated with his jobs during his ten­
ure, showing that none of the meas  ured air 
samples exceeded 20 µg/m3 and most were 
< 10 µg/m3. Although the fluoride furnaces 
had a ventilated hood system, fuming some­
times exceeded the ventilation system’s capac­
ity, resulting in the operators calling for an 
evacua  tion. Fluoride furnace operators nor­
mally remained in the furnace area during 
evacuations, wearing a negative­pressure half­
face respirator. The patient was present for 
21 evacuations in his 7 weeks of employment, 
which was considered by the company to be 
Figure 3. Summary of lung function and beryllium exposure of case 2. (A) Results of pulmonary function tests before, during, and after acute work-related illness. 
(B) TWA and quarterly DWA airborne beryllium exposures in patient’s departments during this time period. Abbreviations: L, medical leave; M, maintenance 
department exposures (beryllium metal, beryllium oxide, copper-beryllium alloy); P, metals production department exposures (beryllium metal, beryllium oxide, 
beryllium fluoride, ammonium beryllium fluoride, ammonium fluoride, magnesium fluoride). 
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an unusually high number. The 8­hr con­
tinuous GA air samples during these evacua­
tions showed an average beryllium air level of 
3.7 µg/m3 and a maximum of 15.6 µg/m3.
On 7 July 1981, the patient’s FVC had 
fallen to 3.36 L (72% predicted) and DLCO 
to 15.7 mL/min/mmHg (57% predicted). 
A BeLPT drawn that day had a stimula­
tion index of 2.0 (normal range, 1.2–2.0). 
By 21 July 1981, his FVC had increased to 
4.12 L (89% predicted) and DLCO to 25.0 
(91% predicted). A repeat BeLPT was abnor­
mal (stimulation index of 5.8). In early 
August, BAL at the NIH was remarkable for 
25% lymphocytes. The skin ulcers were heal­
ing, and the cough had resolved.
On 13 August 1981 the patient returned 
to work at the beryllium plant, restricted from 
working in the furnace area. A BeLPT drawn 
2 days prior was normal (stimulation index of 
1.1). His position on return to the plant was 
in maintenance, where he was likely exposed 
to less soluble or insoluble forms of beryllium. 
Pulmonary function subsequently returned 
to baseline (Figure 3A). He was laid off from 
work on 16 October 1981. On 12 April 1982, 
repeat BAL at the NIH had 1% lymphocytes.
In December 1982, the patient had 
a chest radio  graph that showed a rounded 
soft tissue density in the left lower lung field. 
BeLPT at that time was normal (stimula­
tion index of 1.3). On 7 February 1983, a 
chest computed tomography study at the 
NIH reportedly showed a left­lung nodule, 
two right­lung nodules, and multiple small, 
poorly defined parenchymal lesions bilaterally. 
Open lung biopsy of the left­lung nodule, 
performed to rule out malignancy, revealed 
non  caseating granulomas. Fungal and myco­
bacterial stains and cultures of the biopsied 
tissue were negative. The patient returned to 
work at the beryllium production plant on 
26 March 1984 in the laundry and later as a 
janitor, still restricted from the furnace area. 
He left the plant in 1992 because of CBD.
Historical Literature Review
Physicians caring for workers with acute reac­
tions to beryllium in the 1940s described der­
matitis, nasopharyngitis, tracheo  bronchitis, and 
pneumonitis that developed days to months 
after initiation of employment (DeNardi 
et al. 1949; Van Ordstrand et al. 1945). 
Dermatitis, an eczematous process mainly on 
exposed skin, affected 25% of new employees 
and was noted 3–10 days after initial expo­
sure to beryllium salts (DeNardi et al. 1949). 
Respiratory manifestations appeared on a con­
tinuum. Nasopharyngitis was marked by nasal 
and throat discomfort, mild epistaxis, diffuse 
mucous membrane edema and hyperemia, 
and occasional fissuring (Van Ordstrand et al. 
1945). It often accompanied tracheo  bronchitis, 
which was characterized by non  productive 
cough with occasional hemoptysis, and in some 
cases by low­grade fever, dyspnea, anorexia, 
and weight loss. Examination of workers with 
tracheo  bronchitis revealed early inspiratory 
rales and decreased vital capacity. Those with 
tracheo  bronchitis who continued to work could 
develop pneumonitis, the most severe form of 
the acute reaction. Pneumonitis manifested 
the symptoms and signs of tracheo  bronchitis, 
plus chest pain, severe dyspnea, fatigue, and, 
in many cases, cyanosis. Although most respi­
ratory disease was insidious in onset, taking 
several weeks to manifest, a more fulminating 
form of respiratory disease was recognized after 
“brief but massive” exposures (DeNardi et al. 
1953); in these cases, symptoms developed 
approximately 72 hr after exposure. 
Pneumonitis was distinguished from 
tracheo  bronchitis principally by bilateral 
changes on chest radiograph that appeared 
1–3 weeks after onset of symptoms (DeNardi 
et al. 1953; Van Ordstrand et al. 1945). 
Radio  graphic changes were marked initially by 
diffuse haziness, followed by the development 
of irregular areas of infiltration with promi­
nent peri  bronchial markings, and finally by the 
resolution of the infiltration and appearance of 
nodules scattered throughout the lungs (Van 
Ordstrand et al. 1945). In those who survived, 
clearing of the chest radiograph occurred 
over the course of one or more months (Van 
Ordstrand et al. 1945). Ten percent of those 
who developed pneumonitis died (DeNardi 
et al. 1953).
Pathologic review of lung tissue from fatal 
cases revealed an inflammatory exudate and 
formation of new connective tissue (Dutra 
1948; Freiman and Hardy 1970; Hazard 
1959; Machle et al. 1948; Van Ordstrand et al. 
1945; Vorwald 1948). Alveoli contained fluid 
and a predominance of large mono  nuclear 
cells, along with moderate numbers of lym­
phocytes and plasma cells; polymorphonuclear 
leukocytes were uncommon. Lymphocytes 
and plasma cells were also found infiltrating 
the interstitium. In addition to these find­
ings of a non  specific inflammatory process, 
Vorwald (1948) described the proliferation of 
local histio  cytes in some cases as evidence of 
some organization to the inflammation. Dutra 
(1948) noted that in some cases, clasmato­
cytes (macro  phages) could be seen surround­
ing fibrinoid material in alveoli, and these cells 
were sometimes fused to form multinucleated 
giant cells; others also noted occasional giant 
cells (Freiman and Hardy 1970). In several 
cases, Dutra (1948) found septal nodules com­
prising fibroblasts, lympho  cytes, and plasma 
cells, as well as early granulomas. These find­
ings of an evolution from non  specific inflam­
mation to granulomatous changes led him to 
conclude that there was “evidence of transition 
of the pathologic lesions of the acute condition 
to those of the chronic one” (Dutra 1948).
The treating physicians in the 1940s attrib­
uted acute reactions to exposure to soluble 
beryllium salts, distinguishing the signs and 
symptoms they observed from infection by 
applying the term “chemical” to the disease 
process. Early impressions were that hypersen­
sitivity played a role in the pathophysiology. 
The physicians observed that a large proportion 
of workers with severe dermatitis had a recur­
rence of skin manifestations when exposed 
again, despite protective precautions (DeNardi 
et al. 1949). Furthermore, new workers who 
manifested dermatitis were more likely to go 
on to develop respiratory symptoms, such that 
dermatitis was “considered a rough indicator of 
individual susceptibility to pulmonary or bron­
chial irritation” (DeNardi et al. 1949). Indeed, 
the observations that the dermatitis generally 
required several days to manifest and that the 
radio  graphic changes of the pneumonitis did 
not appear for a week or more after the onset 
of symptoms suggested that direct toxic or irri­
tant mechanisms were not solely responsible. 
For the pneumonitis, the fact that the mag­
nitude of the exposure was not consistently 
related to the occurrence of disease (in some 
cases, “no such relation could be established”) 
was further evidence that “individual sensitiv­
ity . . . undoubtedly . . . contributed to the 
occurrence and severity of disease” (DeNardi 
et al. 1949). Positive results of patch tests with 
various forms of beryllium in patients with der­
matitis (or, in several cases, acute pneumonitis) 
provided confirmatory evidence of immune 
system involvement (Curtis 1951, 1959; Shima 
1971).
These important early clues to a possible 
immune mechanism of ABD were dis  regarded 
by later investigators, who used the term 
“chemical” to refer to a more traditional dose­
dependent inhalational intoxication akin to 
those of “phosgene, nitric oxide, and phospho­
rus oxychloride” (Sterner and Eisenbud 1951). 
Despite an acknowledged lack of sufficient data 
on the “relationship between atmospheric con­
centrations and incidence of [acute respiratory] 
disease,” these investigators (Eisenbud et al. 
1948) concluded that airborne exposures to 
beryllium salts at concentrations > 100 µg/m3 
could produce pneumonitis and that concen­
trations > 1 mg/m3 would consistently do so 
among all exposed individuals (Eisenbud et al. 
1948; Sterner and Eisenbud 1951). They rec­
ognized that earlier authors had not been able 
to establish such an exposure–response rela­
tionship (DeNardi et al. 1949; Sterner and 
Eisenbud 1951). However, they reasoned that 
cases of ABD that did not conform to these 
toxicologic parameters reflected the effect of 
repeated exposures, leading to a cumulation of 
injury that would lower the threshold for respi­
ratory symptoms (Sterner and Eisenbud 1951). 
They acknowledged the longer delay between 
exposure and disease manifestations compared Cummings et al.
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with other causes of acute chemical pneumoni­
tis, but they did not offer an explanation for 
this discrepancy (Sterner and Eisenbud 1951). 
In contrast to their concept of ABD’s resulting 
from a chemical process, they hypothesized 
that CBD was immune­mediated, postulat­
ing the involvement of an antibody response 
(Sterner and Eisenbud 1951).
Discussion
The idea of different mechanisms behind 
beryllium’s acute and chronic effects has been 
reiterated in the literature and in textbooks in 
the years since it was first proposed (Balmes 
2005; Becklake and Cowie 2000; Churg and 
Green 1998; Williams 1988). Clinical, epi­
demiologic, and laboratory­based investiga­
tions subsequently have shed much light on 
the mechanism of CBD. We now know 
that cellular (rather than humoral) immu­
nity is responsible for its manifestations, that 
increased susceptibility is conferred through 
major histocompatibility complex class II 
genetic variants, and that sensitization to beryl­
lium can be detected via specific lymphocytic 
proliferative responses measured by the BeLPT 
(Amicosante and Fontenot 2006; Kreiss et al. 
1994; McCanlies et al. 2004). The decline in 
the occurrence of ABD, however, has limited 
research into its mechanism. Instead, with only 
rare suggestions of an immunologic process 
(Kreiss et al. 2007; Newman and Maier 2003), 
the conceptualization of ABD as a toxic chemi­
cal irritation has remained virtually unchanged. 
This conceptualization is reflected in descrip­
tions of ABD as indistinguishable from other 
chemical inhalational injuries, dose­related 
exposures, and secondary to high­intensity 
exposures. Such descriptions fail to account 
for the delayed onset of symptoms and radio­
graphic manifestations, the specific pathologic 
characteristics of an evolving granulomatous 
inflammation, and the lack of a clear exposure–
response relationship.
The two cases we describe here of acute 
dermal and respiratory disease that occurred 
in beryllium metal production workers share 
many features with the cases of ABD reported 
in the 1940s. Like those earlier cases, both 
workers experienced onset of dermatitis about 
10 days after starting work in the furnace areas. 
In case 2, epistaxis and mucosal erosions were 
evidence of the naso  pharyngitis described by 
the earlier investigators. Both workers subse­
quently developed respiratory symptoms and 
marked declines in FVC and DLCO, indicating 
pneumonitis, as observed in the 1940s. Both 
had remarkable improvement in symptoms 
and objective findings after removal from the 
workplace, again consistent with the 1940s 
experience. In case 1, dermal and respiratory 
symptoms and pulmonary function abnor­
malities recurred upon return to the same 
work environment; in case 2, the worker was 
reassigned away from the furnace area and did 
not have a recurrence of acute symptoms. In 
case 1, delayed radio  graphic changes during 
the second, more prolonged episode of acute 
illness included scattered nodules, a finding 
also noted late in the course of 1940s cases. 
Thus, their clinical patterns and occupational 
exposures, so similar to those described earlier, 
indicate that these two workers had ABD.
The clinical courses and diagnostic data of 
these cases provide evidence of a shared immu­
nologic mechanism between ABD and CBD. 
The timing of the dermatitis suggests a delayed­
type hyper  sensitivity reaction rather than an 
irritative process, which would be expected to 
present more rapidly after exposure. Similarly, 
the progression of respiratory symptoms and 
signs over weeks or months, accompanied in 
case 1 by substantial weight loss, is more con­
sistent with an immuno  logic process than a 
chemical insult. The abnormal BeLPT results 
at the time of acute illness indicate the pres­
ence of a cell­mediated immune response to 
beryllium concurrent with the acute reaction to 
beryllium. And the lymphocytic predominance 
seen on BAL fluid analysis at the time of acute 
illness demonstrates a specific alveolitis, as seen 
in CBD, rather than the non  specific inflamma­
tory process of an irritant.
In both cases, lung biopsy performed about 
18 months after acute illness, when the work­
ers were asymptomatic, revealed non  caseating 
granulomas, a hallmark of CBD. That ABD 
can precede and even “merge imperceptibly 
with” (Freiman and Hardy 1970) CBD has 
been reported previously (Freiman and Hardy 
1970; Hardy 1965; Rees 1979; Tepper et al. 
1961). Indeed, Hardy (1951) noted early on 
that in some cases, CBD could follow ABD 
“after a variable period of time, with or with­
out further beryllium exposure.” In the sur­
vey of beryllium production facility workers 
(Kreiss et al. 1997), we found that workers who 
reported a history of cough or breathing prob­
lems related to beryllium fluoride had twice the 
odds of beryllium sensitization or CBD than 
did workers without that history (Cummings 
KJ, Kreiss K, unpublished data). Explanations 
for an association between ABD and subse­
quent CBD other than a shared immunologic 
mecha  nism (e.g., the role of a common rele­
vant exposure) are difficult to refute unequivo­
cally in the absence of experimental data. Yet 
as the cases presented here demonstrate, the 
concept of a disease continuum whereby cell­
mediated immune recognition of beryllium 
produces acute symptoms, is active during 
asymptomatic periods, and is responsible for 
chronic impairment, is by far the most parsi­
monious and   consistent explanation.
The modern decline in reports of ABD has 
mirrored the decrease in average exposures. 
In their 2004 report of new cases, Kim et al. 
(2004) noted beryllium concentrations ranging 
from 3 to 112 µg/m3, suggesting that affected 
workers may have had unusually high expo­
sures for the contemporary industrial setting. 
Yet for the workers in the cases in the present 
study, the available industrial hygiene data rep­
resent the highest TWA exposures for tasks or 
work areas on a given day associated with the 
jobs they held. Coupled with the reported use 
of respirators for some tasks and during upset 
conditions, the exposure data suggest that these 
cases of ABD occurred at exposures less than 
the high concentrations commonly described 
as necessary to provoke an acute response. This 
finding is consistent with the lack of a reli­
able exposure–response relationship noted by 
the earlier investigators (DeNardi et al. 1949), 
and with the Japanese experience, where pneu­
monitis was noted with exposures as low as 
25 µg/m3 and bronchitis was reported with 
even lower exposures (Shima 1971).
The present investigation has several limi­
tations. Although the two cases presented 
here offer a relative wealth of diagnostic infor­
mation, they do not represent an exhaustive 
review of all cases. Furthermore, the varia­
tions in BeLPT results over time appear to 
provide a conflicting message about the role 
of cell­mediated immunity in ABD. Although 
consistently abnormal results throughout the 
acute illness may have been more convinc­
ing, the test’s specificity (99%) is substantially 
higher that its sensitivity (66%) (Middleton 
et al. 2006). Thus, the greater challenge is 
reconciling the finding of abnormal BeLPT 
results during acute illness with a chemical 
mechanism of ABD. Another limitation is that 
although the available air sampling data were 
comprehensive and our presentation of the 
data emphasized highest TWA values, some 
exposures may have been underestimated, par­
ticularly if instantaneous peaks occurred dur­
ing short­ or long­duration sampling and were 
subject to averaging. Furthermore, we cannot 
rule out the possibility of unusually elevated 
airborne concentrations of beryllium that went 
unmeasured.
Despite these limitations, these cases 
provide compelling evidence in support of 
the hypothesis that ABD, like CBD, is an 
immune­mediated phenomenon. Why some 
individuals exposed to beryllium mani­
fest ABD only, others CBD only, and still 
others both ABD and CBD, is likely multi­
factorial. Investigators have highlighted the 
chemical form of beryllium to which a per­
son is exposed. The initial reports of ABD 
emphasized the role of exposure to soluble 
forms of beryllium (DeNardi et al. 1949, 
1953; Van Ordstrand et al. 1945), and the 
hypothesis that solubility influenced the mani­
festation of ABD versus CBD was put forth 
early on (Machle et al. 1948; Waksman 1959). 
Solubility facilitates absorption, with salts 
being more readily dissolved by sweat (Curtis Acute beryllium disease
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1951) and respiratory secretions. Furthermore, 
soluble beryllium, as suggested by Waksman 
(1959), would be “active in complexing with 
body constituents,” producing high local anti­
gen concentrations that lead to a vigorous, 
acute response, whereas insoluble beryllium 
would be less reactive and remain unaltered 
for longer periods. Indeed, subsequent research 
has shown that at the neutral pH in airway 
epithelial lining fluid, beryllium ions may 
rapidly complex to form hydroxide (BeOH+) 
and carbonate (BeCO3) compounds (Sutton 
and Burastero 2003) and bind to a range of 
organic acids and proteins (Scott et al. 2008).
Others have noted variations in persis­
tence of different forms of beryllium in the 
body. From 10 months to 5 years after recov­
ery from acute pneumonitis related to soluble 
beryllium salts, follow­up revealed the absence 
of detectable beryllium in the urine of those 
patients who had not returned to working 
with beryllium (DeNardi et al. 1949). In 
contrast, some workers exposed to insolu­
ble forms of beryllium continued to excrete 
beryllium 6 years after removal from exposure 
(DeNardi et al. 1953). More recently, insol­
uble beryllium metal and oxide have been 
shown to have dissolution lifetimes of hun­
dreds of days to years in lung airway epithelial 
lung fluid and alveolar macrophage phago­
lysosomal fluid (Finch et al. 1988; Stefaniak 
et al. 2006). Autopsy studies have confirmed 
that beryllium particles are identifiable in 
granulomas formed in the lungs of individuals 
with CBD years after exposure ceased (Butnor 
et al. 2003; Sawyer et al. 2005; Williams and 
Wallach 1989). Thus, Stefaniak et al. (2003, 
2008) hypothesized that exposure aerosol 
physical properties, chemical properties, and 
physico  chemical properties control develop­
ment of beryllium lung burdens, and that the 
ongoing presence of a lung reservoir of beryl­
lium may be necessary for the development 
of CBD.
Although early investigation demon  strated 
that patch testing with poorly soluble beryl­
lium compounds (metal, oxide) and control 
anions and acids alone failed to produce a 
reaction (Curtis 1951), it is possible that coin­
cident irritant exposures (e.g., ammonia or 
hydrofluoric acid from a fluoride furnace or 
magnesium fluoride from a reduction furnace) 
play a contributory role in disease manifesta­
tion. Investigations of allergic contact derma­
titis have found evidence of interplay between 
irritation and sensitization. Irritant dermatitis 
can increase the induction of allergic derma­
titis, through mechanisms that include skin 
barrier disruption and cytokine release by non­
immune dermal cells (Burkhart 2006; Smith 
et al. 2002; Zhang and Tinkle 2000). There 
is evidence for an analogous process in the 
respiratory tract: irritants such as diesel exhaust 
(Kleinman et al. 2007; Wichmann 2007) and 
tobacco smoke (Diaz­Sanchez et al. 2006) 
can exacerbate responses to known allergens. 
Thus, it is feasible that coincident irritation 
of the skin or respiratory tract could promote 
sensitization and the development of ABD. 
The role of beryllium’s chemical properties in 
the development of sensitization and disease 
remains an area of active inquiry (Day et al. 
2005; Stefaniak et al. 2003, 2004, 2006).
The physicians caring for the work­
ers we describe did not initially recognize 
their patients’ symptoms as those of ABD. 
Their reluctance to use this diagnosis likely 
reflected the prevailing notion of ABD as a 
consequence of particularly high exposures. 
Publications insisting that ABD had become 
rare because of improved industrial hygiene 
were undoubtedly influential (DeNardi 1959; 
DeNardi et al. 1953; Freiman and Hardy 
1970; Williams 1977). Even when beryllium 
was implicated, an increased risk of CBD was 
not appreciated. Thus whereas treating physi­
cians in the 1940s recommended avoidance 
of further beryllium exposure following ABD 
diagnosis (Van Ordstrand et al. 1945), these 
two workers continued to be exposed, ulti­
mately in work areas with insoluble beryllium. 
A better understanding of the patho  genesis 
of ABD may allow for a more protective 
approach in the future.
Conclusions
Initial reports of ABD described dermal and 
respiratory reactions that were delayed in onset, 
did not follow clear exposure–response pat­
terns, and often recurred upon reexposure. 
Pathology showed an evolution from non­
specific mono  nuclear inflammation to more 
specific granulomatous lesions. This telling evi­
dence was over  shadowed by subsequent asser­
tions that ABD represented a dose­dependent 
chemical injury without patho  physiologic 
relation to the immune­mediated process of 
CBD. The cases presented here suggest that 
rather than two distinct clinical entities, ABD 
and CBD represent points on a continuum 
of hypersensitivity reactions to beryllium. 
Differences in disease presentation and pro­
gression are likely influenced by the solubility 
of the beryllium compound involved and pos­
sibly by coexposures. Prudence dictates limi­
tation of further beryllium exposure in both 
ABD and CBD.
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